Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Unmet expectations and smoking prove key factors in quitting bladder medication

May 13, 2010 By EurekAlert

Nine out of ten patients who discontinued their overactive
bladder (OAB) medication said it was because it didn’t work as
expected or they couldn’t tolerate it, according to research in the
May issue of the urology journal BJUI.

US researchers also discovered that smokers, men with enlarged
prostates and people with bladder infections are also significantly
more likely to stop taking prescription drugs for bladder
problems.

The team surveyed 6,577 adults who said in a National Family
Opinion survey that they had been prescribed medication for OAB in
the last 12 months and 82% responded.

They found that patients who had abandoned their medication were
much more likely to be bothered by OAB symptoms than those who had
persisted and more likely to have had a diagnosis for a condition
such as OAB or incontinence.

A quarter of the 5,392 who responded had discontinued one or
more of their OAB drugs in the last year, with the majority giving
multiple reasons. Just under half (46%) said the medication didn’t
work as expected, 23% learnt to get by without medication and 21%
reported side effects. Other reasons included cost, change of
insurance status, not wanting to use medication, advice from
healthcare professionals and health improvements. A quarter said
they had switched to a new medication.

“Encouraging people with long-term health conditions to persist
with medication is common and problematic” says Professor Linda
Brubaker from Loyola University, Chicago, who co-authored the paper
with urology colleagues from across the USA.

“Recent database studies suggest that the number of OAB patients
who stop taking their medication is much higher than clinical
trials would suggest.

“It is important to identify why people stop taking their
medication as persistence with medication is generally associated
with positive health outcomes and reductions in healthcare resource
use and costs.”

Key findings of the study included:

  • Bothersome OAB symptoms were reported more frequently by
    patients who had discontinued their medication: 10% more were
    “quite a bit more” bothered about needing to urinate at night, 13%
    more with urgency, 9% more with incontinence and 11% more with
    frequency.

  • More patients in the discontinued medication group had a
    medical diagnosis of OAB (10% more than the group who persisted),
    incontinence (8% more), bladder infection (6% more) and urinary
    retention (4% more).

  • There were no statistically significant differences in sex, age
    or race, household income, health insurance and prescription
    insurance between the two groups and relatively minor differences
    when it came to beliefs about OAB, including what was normal and
    how it could be treated.

  • A third of the people who had discontinued gave one reason for
    stopping, a third gave two reasons and a third gave three
    reasons.

A second paper in the May issue of BJUI focuses on the
results of a six-month follow-up on the patients who were still
taking their medication at the time of the above study, based on an
84% response rate.

This showed that 66% were still taking their medication, 18% had
discontinued and 17% had switched medication in the intervening six
months.

Researchers found that a number of factors increased the chances
of patients discontinuing their OAB medication, including:

  • Being a current smoker (up 80%)
  • Having an enlarged prostate (up 74%) or a bladder infection (up
    54%).
  • Believing that bladder medication caused severe side effects
    (up 111%) or not knowing whether it did or not (up 76%).
  • Being bothered “quite a bit more” by a sudden urge to urinate
    with little or no warning (up 54%).

However, being on multiple prescriptions or having had an
episode of incontinence in the last week increased the odds of
compliance.

“To our knowledge this is the first study to ask patients why
they discontinued their OAB medication” says Professor Brubaker.
“We believe that our findings point to the need for healthcare
providers to foster realistic expectations about how effective OAB
treatment will be and about any side effects.

“We also believe that healthcare providers should discuss
lifestyle changes, such as smoking cessation, urgency control
strategies and pelvic floor muscle training with OAB patients.
Research has shown that providing behavioural advice as well as
drugs to patients with OAB can improve both symptoms and
satisfaction with treatment.”

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech